Navamedic ASA: Trading Update
Oslo, 4 July 2022 – Navamedic ASA (OSE: NAVA) today announces a trading update based on updated estimated revenue growth in excess of 30% organic growth for the first half of 2022. The high revenue growth is a result of a strong June 2022 and is driven by significant demand for Mysimba as well as other key products in the portfolio.As the company’s preliminary consolidated financial results for the second quarter of 2022 (and hence first half of the year) represent a noticeable improvement compared to expectations, the company has decided to provide a trading update based on estimated